10 Apr

Bayer-Monsanto Merger Approval Came after Divestments

WRITTEN BY Adam Jones

Addressing concerns

In Bayer-Monsanto Deal Receives European Union Approval, we discussed some of the concerns that delayed the approval of the Bayer-Monsanto (MON) merger by antitrust officials in various jurisdictions (XLB). Some of the concerns included higher prices due to monopoly, challenges due to research and development and innovation, a higher concentration that might lead to market dominance, and limited choices for customers.

Bayer-Monsanto Merger Approval Came after Divestments

Settling concerns with divestments

Large overlaps in the business have been a concern for antitrust regulators. Bayer and Monsanto are complementary businesses with minimal overlap. For example, Monsanto’s core is the seed genetics business, while Bayer’s core is the pesticides business.

According to a Wall Street Journal report on the deal, Bayer agreed to sell its seed-related assets and make similar arrangements in its digital agricultural business in order to meet the US approval requirements.

In another recent deal, PotashCorp (POT) (NTR) and Agrium (AGU) made similar arrangements to divest their businesses to satisfy antitrust concerns.

Monsanto’s earnings

Recently, Monsanto reported its 2Q18 earnings with an EPS (earnings per share) of $3.22, which missed analysts’ mean estimate of $3.30. However, there was a 1% gain in the EPS year-over-year from $3.19 in fiscal 2Q17. To learn more, read Monsanto Released Fiscal 2Q18 Earnings: Some Key Takeaways.

Latest articles

In Q3, billionaire investor Leon Cooperman's top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

In 2018, 3,503 metric tons of gold were produced globally, 1.8% higher than in 2017. Let's look at the world's top gold-producing countries.

TJX Companies (TJX) reported better-than-expected earnings results for the third quarter of fiscal 2020, which ended on November 2.

Despite Canada's legalization of cannabis a year ago, a StatCan survey found that 42% of Canadians have obtained their cannabis from illegal sources.

On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

Roku (ROKU) stock tanked more than 5% on Tuesday during market hours. The company said it will issue nearly 1 million common shares today.